MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses

Adam D. Bachstetter, Zhengqiu Zhou, Rachel K. Rowe, Bin Xing, Danielle S. Goulding, Alyssa N. Conley, Pradoldej Sompol, Shelby Meier, Jose F. Abisambra, Jonathan Lifshitz, D. Martin Watterson, Linda J. Van Eldik

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A prevailing neuroinflammation hypothesis is that increased production of proinflammatory cytokines contributes to progressive neuropathology, secondary to the primary damage caused by a traumatic brain injury (TBI). In support of the hypothesis, post-injury interventions that inhibit the proinflammatory cytokine surge can attenuate the progressive pathology. However, other post-injury neuroinflammatory responses are key to endogenous recovery responses. Therefore, it is critical that pharmacological attenuation of detrimental or dysregulated neuroinflammatory processes avoid pan-suppression of inflammation. MW151 is a CNS-penetrant, small molecule experimental therapeutic that restores injuryor disease-induced overproduction of proinflammatory cytokines towards homeostasis without immunosuppression. Post-injury administration of MW151 in a closed head injury model of mild TBI suppressed acute cytokine up-regulation and downstream cognitive impairment. Here, we report results from a diffuse brain injury model in mice using midline fluid percussion. Low dose (0.5-5.0 mg/kg) administration of MW151 suppresses interleukin-1 beta (IL- 1β) levels in the cortex while sparing reactive microglia and astrocyte responses. To probe molecular mechanisms, we used live cell imaging of the BV-2 microglia cell line to demonstrate that MW151 does not affect proliferation, migration, or phagocytosis of the cells. Our results provide insight into the roles of glial responses to brain injury and indicate the feasibility of using appropriate dosing for selective therapeutic modulation of injurious IL-1β increases while sparing other glial responses to injury.

Original languageEnglish (US)
Article numbere0149451
JournalPLoS One
Volume11
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

interleukin-1
neuroglia
Microglia
Interleukin-1
physiological response
Brain
cytokines
Cytokines
brain
Wounds and Injuries
Neuroglia
Brain models
Brain Concussion
neuropathology
Percussion
Closed Head Injuries
Cytophagocytosis
Molecular Probes
therapeutics
astrocytes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Bachstetter, A. D., Zhou, Z., Rowe, R. K., Xing, B., Goulding, D. S., Conley, A. N., ... Van Eldik, L. J. (2016). MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses. PLoS One, 11(2), [e0149451]. https://doi.org/10.1371/journal.pone.0149451

MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses. / Bachstetter, Adam D.; Zhou, Zhengqiu; Rowe, Rachel K.; Xing, Bin; Goulding, Danielle S.; Conley, Alyssa N.; Sompol, Pradoldej; Meier, Shelby; Abisambra, Jose F.; Lifshitz, Jonathan; Watterson, D. Martin; Van Eldik, Linda J.

In: PLoS One, Vol. 11, No. 2, e0149451, 01.02.2016.

Research output: Contribution to journalArticle

Bachstetter, AD, Zhou, Z, Rowe, RK, Xing, B, Goulding, DS, Conley, AN, Sompol, P, Meier, S, Abisambra, JF, Lifshitz, J, Watterson, DM & Van Eldik, LJ 2016, 'MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses', PLoS One, vol. 11, no. 2, e0149451. https://doi.org/10.1371/journal.pone.0149451
Bachstetter, Adam D. ; Zhou, Zhengqiu ; Rowe, Rachel K. ; Xing, Bin ; Goulding, Danielle S. ; Conley, Alyssa N. ; Sompol, Pradoldej ; Meier, Shelby ; Abisambra, Jose F. ; Lifshitz, Jonathan ; Watterson, D. Martin ; Van Eldik, Linda J. / MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses. In: PLoS One. 2016 ; Vol. 11, No. 2.
@article{745cf88e6bf843edb799f935b982b56a,
title = "MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses",
abstract = "A prevailing neuroinflammation hypothesis is that increased production of proinflammatory cytokines contributes to progressive neuropathology, secondary to the primary damage caused by a traumatic brain injury (TBI). In support of the hypothesis, post-injury interventions that inhibit the proinflammatory cytokine surge can attenuate the progressive pathology. However, other post-injury neuroinflammatory responses are key to endogenous recovery responses. Therefore, it is critical that pharmacological attenuation of detrimental or dysregulated neuroinflammatory processes avoid pan-suppression of inflammation. MW151 is a CNS-penetrant, small molecule experimental therapeutic that restores injuryor disease-induced overproduction of proinflammatory cytokines towards homeostasis without immunosuppression. Post-injury administration of MW151 in a closed head injury model of mild TBI suppressed acute cytokine up-regulation and downstream cognitive impairment. Here, we report results from a diffuse brain injury model in mice using midline fluid percussion. Low dose (0.5-5.0 mg/kg) administration of MW151 suppresses interleukin-1 beta (IL- 1β) levels in the cortex while sparing reactive microglia and astrocyte responses. To probe molecular mechanisms, we used live cell imaging of the BV-2 microglia cell line to demonstrate that MW151 does not affect proliferation, migration, or phagocytosis of the cells. Our results provide insight into the roles of glial responses to brain injury and indicate the feasibility of using appropriate dosing for selective therapeutic modulation of injurious IL-1β increases while sparing other glial responses to injury.",
author = "Bachstetter, {Adam D.} and Zhengqiu Zhou and Rowe, {Rachel K.} and Bin Xing and Goulding, {Danielle S.} and Conley, {Alyssa N.} and Pradoldej Sompol and Shelby Meier and Abisambra, {Jose F.} and Jonathan Lifshitz and Watterson, {D. Martin} and {Van Eldik}, {Linda J.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0149451",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses

AU - Bachstetter, Adam D.

AU - Zhou, Zhengqiu

AU - Rowe, Rachel K.

AU - Xing, Bin

AU - Goulding, Danielle S.

AU - Conley, Alyssa N.

AU - Sompol, Pradoldej

AU - Meier, Shelby

AU - Abisambra, Jose F.

AU - Lifshitz, Jonathan

AU - Watterson, D. Martin

AU - Van Eldik, Linda J.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - A prevailing neuroinflammation hypothesis is that increased production of proinflammatory cytokines contributes to progressive neuropathology, secondary to the primary damage caused by a traumatic brain injury (TBI). In support of the hypothesis, post-injury interventions that inhibit the proinflammatory cytokine surge can attenuate the progressive pathology. However, other post-injury neuroinflammatory responses are key to endogenous recovery responses. Therefore, it is critical that pharmacological attenuation of detrimental or dysregulated neuroinflammatory processes avoid pan-suppression of inflammation. MW151 is a CNS-penetrant, small molecule experimental therapeutic that restores injuryor disease-induced overproduction of proinflammatory cytokines towards homeostasis without immunosuppression. Post-injury administration of MW151 in a closed head injury model of mild TBI suppressed acute cytokine up-regulation and downstream cognitive impairment. Here, we report results from a diffuse brain injury model in mice using midline fluid percussion. Low dose (0.5-5.0 mg/kg) administration of MW151 suppresses interleukin-1 beta (IL- 1β) levels in the cortex while sparing reactive microglia and astrocyte responses. To probe molecular mechanisms, we used live cell imaging of the BV-2 microglia cell line to demonstrate that MW151 does not affect proliferation, migration, or phagocytosis of the cells. Our results provide insight into the roles of glial responses to brain injury and indicate the feasibility of using appropriate dosing for selective therapeutic modulation of injurious IL-1β increases while sparing other glial responses to injury.

AB - A prevailing neuroinflammation hypothesis is that increased production of proinflammatory cytokines contributes to progressive neuropathology, secondary to the primary damage caused by a traumatic brain injury (TBI). In support of the hypothesis, post-injury interventions that inhibit the proinflammatory cytokine surge can attenuate the progressive pathology. However, other post-injury neuroinflammatory responses are key to endogenous recovery responses. Therefore, it is critical that pharmacological attenuation of detrimental or dysregulated neuroinflammatory processes avoid pan-suppression of inflammation. MW151 is a CNS-penetrant, small molecule experimental therapeutic that restores injuryor disease-induced overproduction of proinflammatory cytokines towards homeostasis without immunosuppression. Post-injury administration of MW151 in a closed head injury model of mild TBI suppressed acute cytokine up-regulation and downstream cognitive impairment. Here, we report results from a diffuse brain injury model in mice using midline fluid percussion. Low dose (0.5-5.0 mg/kg) administration of MW151 suppresses interleukin-1 beta (IL- 1β) levels in the cortex while sparing reactive microglia and astrocyte responses. To probe molecular mechanisms, we used live cell imaging of the BV-2 microglia cell line to demonstrate that MW151 does not affect proliferation, migration, or phagocytosis of the cells. Our results provide insight into the roles of glial responses to brain injury and indicate the feasibility of using appropriate dosing for selective therapeutic modulation of injurious IL-1β increases while sparing other glial responses to injury.

UR - http://www.scopus.com/inward/record.url?scp=84960969980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960969980&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0149451

DO - 10.1371/journal.pone.0149451

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0149451

ER -